Sirtris Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering

  
    
  
  
    
      Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical 
      company focused on discovering and developing small molecule drugs to 
      treat diseases of aging such as Type 2 Diabetes, today announced the 
      pricing of its initial public offering of 6,000,000 shares of its common 
      stock at $10.00 per share, before underwriting discounts and 
      commissions. All of the common stock is being offered by Sirtris. In 
      addition, Sirtris has granted the underwriters a 30-day option to 
      purchase up to an additional 900,000 shares to cover over-allotments, if 
      any. J.P. Morgan Securities Inc. is acting as the sole book-running 
      manager and CIBC World Markets Corp., Piper Jaffray & Co., JMP 
      Securities LLC, and Rodman & Renshaw, LLC are acting as co-managers for 
      the offering. The shares will trade on the NASDAQ Global Market under 
      the symbol "SIRT."
    
    
      A registration statement relating to these securities was declared 
      effective by the Securities and Exchange Commission on May 22nd, 
      2007. The public offering is being made by means of a written 
      prospectus. Copies of the final prospectus relating to the offering may 
      be obtained from: J.P. Morgan Securities Inc., Attention: Prospectus 
      Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245. 
      Phone: [phone]. Email: [e-mail].
    
    
      This press release shall not constitute an offer to sell or the 
      solicitation of an offer to buy, nor shall there be any sale of these 
      securities in any state in which such offer, solicitation or sale would 
      be unlawful prior to their registration or qualification under the 
      securities laws of any such state.
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes. The 
      company's headquarters are in Cambridge, Massachusetts.